A large observational study presented at the 2026 ASCO Annual Meeting found that GLP-1 medications (such as Ozempic and Wegovy) may lower breast cancer risk by approximately 30% in women with overweight or obesity. After matching for age, BMI, breast density, and diabetes status, GLP-1 users had significantly lower breast cancer incidence than non-users. Excess body fat is a known driver of breast cancer, especially after menopause, because it increases estrogen production, chronic inflammation, and insulin resistance. GLP-1 agonists promote substantial weight loss and improve metabolic health, which likely explain the observed risk reduction. However, the study is observational and cannot prove causation. A clinical trial called INSPIRE is now underway to test whether these drugs directly prevent breast cancer.

Beyond GLP-1 drugs, proven prevention strategies include maintaining a healthy weight, regular physical activity, limiting alcohol intake, breastfeeding, and avoiding unnecessary hormone replacement therapy. For women at high genetic or familial risk, anti-estrogen medications such as tamoxifen or raloxifene, and even risk-reducing mastectomy, are effective options. Equally critical is rapid detection. Routine mammography remains the gold standard for early diagnosis. Emerging technologies like point-of-care ultrasound and liquid biopsy assays – which detect tumor DNA or circulating cancer cells from a simple blood draw – can provide results in minutes to hours, enabling faster clinical decisions.

In summary, GLP-1 drugs represent a promising future tool for breast cancer prevention, but confirmatory trials are needed. Meanwhile, lifestyle modifications, established high-risk interventions, and regular screening remain the cornerstones of breast cancer control. Combining prevention with rapid, accessible detection offers the best strategy to reduce suffering and save lives. Every woman should discuss personalized risk reduction and a suitable screening plan with her healthcare provider.